78 related articles for article (PubMed ID: 2549225)
41. The in vitro stability in human plasma of two different technetium-99m-fibrinogen compounds.
Spicher E; Gieux B; Fridrich R
Experientia; 1984 Jun; 40(6):543-4. PubMed ID: 6327361
[TBL] [Abstract][Full Text] [Related]
42. [The preparation of 99mTc-NGA instant lyophilized kit for hepatic imaging].
Guan C; Chen Q; Tan T
Hua Xi Yi Ke Da Xue Xue Bao; 1993 Dec; 24(4):429-32. PubMed ID: 8150449
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, and biological evaluation of catecholamine vehicle for studying dopaminergic system.
Singh P; Kumar V; Aggarwal S; Tiwari AK; Chuttani K; Pratap R; Mishra AK
Chem Biol Drug Des; 2013 Aug; 82(2):226-32. PubMed ID: 23601203
[TBL] [Abstract][Full Text] [Related]
44. [Measurement of hepatic plasma volume using Tc 99m albumin by double injection-single sampling method (author's transl)].
Kawakami K; Katsuyama N; Mochizuki S; Kameda H; Nakai M; Kamiya A
Kaku Igaku; 1979 Feb; 16(1):23-7. PubMed ID: 439488
[No Abstract] [Full Text] [Related]
45. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.
Virgolini I; Müller C; Klepetko W; Angelberger P; Bergmann H; O'Grady J; Sinzinger H
Br J Cancer; 1990 Jun; 61(6):937-41. PubMed ID: 2164838
[TBL] [Abstract][Full Text] [Related]
46. In vitro quantification of asialoglycoprotein receptor density from human hepatic microsamples.
Vera DR; Topcu SJ; Stadalnik RC
Methods Enzymol; 1994; 247():394-402. PubMed ID: 7898367
[No Abstract] [Full Text] [Related]
47. [Percutaneous reabsorption of Tc 99m heparinoid].
Klug W; Johannsen B
Z Exp Chir Transplant Kunstliche Organe; 1988; 21(5):281-4. PubMed ID: 2461619
[TBL] [Abstract][Full Text] [Related]
48. The evolution of (99m)Tc-NGA as a clinically useful receptor-binding radiopharmaceutical.
Stadalnik RC; Vera DR
Nucl Med Biol; 2001 Jul; 28(5):499-503. PubMed ID: 11516694
[No Abstract] [Full Text] [Related]
49. [Physicochemical and radiopharmacokinetic characteristics of Tc 99m tetracycline: a tumor marker].
de Murphy CA; Vidal A; Cortés P; Coo JJ; Papadakis M; Eberstadt P; Melchum L
Rev Invest Clin; 1987; 39(4):349-53. PubMed ID: 3451316
[No Abstract] [Full Text] [Related]
50. Plasma transport of 99mTc-p-butyl-IDA.
Champailler A; Gremillet E; Decousus M; Kassir A; Voutay M; Healy JC
Eur J Nucl Med; 1985; 10(9-10):437-40. PubMed ID: 4006985
[TBL] [Abstract][Full Text] [Related]
51. [Edematous syndromes caused by capillary hyperpermeability. Diffuse angioedema].
Lagrue G; Behar A; Laurent J
Presse Med; 1988 Jun; 17(24):1234, 1237-8. PubMed ID: 2969561
[No Abstract] [Full Text] [Related]
52. Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.
Fele-Paranj A; Saboury B; Uribe C; Rahmim A
EJNMMI Radiopharm Chem; 2024 Jan; 9(1):6. PubMed ID: 38252191
[TBL] [Abstract][Full Text] [Related]
53. Proceedings: Measurement of plasma volume using human serum albumin labelled with technetium.
Holroyd AM; Lawrence AC; Parker C; Davies M
J Clin Pathol; 1975 Sep; 28(9):756-7. PubMed ID: 1165310
[No Abstract] [Full Text] [Related]
54. Correction: Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding.
Fele-Paranj A; Saboury B; Uribe C; Rahmim A
EJNMMI Radiopharm Chem; 2024 Mar; 9(1):22. PubMed ID: 38504056
[No Abstract] [Full Text] [Related]
55. Concepts for design and analysis of receptor radiopharmaceuticals: The Receptor-Binding Radiotracers series of meetings provided the foundation.
Krohn KA; Vera DR
Nucl Med Biol; 2021 Jan; 92():5-23. PubMed ID: 32331709
[TBL] [Abstract][Full Text] [Related]
56. γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).
Azad AK; Rajaram MV; Metz WL; Cope FO; Blue MS; Vera DR; Schlesinger LS
J Immunol; 2015 Sep; 195(5):2019-29. PubMed ID: 26202986
[TBL] [Abstract][Full Text] [Related]
57. Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.
Qin Z; Hall DJ; Liss MA; Hoh CK; Kane CJ; Wallace AM; Vera DR
J Biomed Opt; 2013 Oct; 18(10):101315. PubMed ID: 23958947
[TBL] [Abstract][Full Text] [Related]
58. A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging.
Emerson DK; Limmer KK; Hall DJ; Han SH; Eckelman WC; Kane CJ; Wallace AM; Vera DR
Radiology; 2012 Oct; 265(1):186-93. PubMed ID: 22753678
[TBL] [Abstract][Full Text] [Related]
59. Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.
Virgolini I; Kornek G; Höbart J; Li SR; Raolerer M; Bergmann H; Scheithauer W; Pantev T; Angelberger P; Sinzinger H
Br J Cancer; 1993 Sep; 68(3):549-54. PubMed ID: 8353045
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
